Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

Alzecure: Historical (External) News

AH

Anders Hedlund

Redeye knew this day was coming. And still, we were caught by some surprise. FDA has granted accelerated approval to aducanumab, the first drug in Alzheimer's that targets the underlying disease pathology. We leave the first note to this news from an Alzecure perspective.

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers